Company intelligence / Profile preview

iDelivery

Reggio di Calabria, Calabria, Italyi-delivery.net ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Lenipsor+ has undergone in vitro and in vivo testing on over 200 patients with results reportedly superior to direct competitors. The product is available as a dermocosmetic gel for improving the appearance of psoriatic plaques. A second product targeting herpes is under development and patenting.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: NanoparticleSmall molecule
Industry: Biotech

Drug pipeline

1 asset

Bulbixin

Preclinical

Partnerships

Collaborations with Italian research centers and universitiesSupported by Italian Trade Agency and regional innovation programs

Beyond the preview

Go deeper on iDelivery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iDelivery.

Explore the full profile